Aerie Pharmaceuticals, Inc.
2030 Main Street, Suite 1500
Irvine, California 92614
July 28, 2017
VIA EDGAR
Suzanne Hayes
Assistant Director
Office of Insurance and Healthcare
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Aerie Pharmaceuticals, Inc. |
| Form10-K |
| Filed March 9, 2017 |
| FileNo. 001-36152 |
Dear Ms. Hayes:
We have received your letter, dated July 19, 2017, regarding the Annual Report onForm 10-K for the fiscal year ended December 31, 2016 filed by Aerie Pharmaceuticals, Inc. (“Aerie” or the “Company”) and in this letter we respond to the Staff’s comments. For your convenience, our response is prefaced by the comment in italicized text.
Item 1. Business
Intellectual Property, page 16
| 1. | Please expand your disclosure in future filings regarding your patent protection for your current product candidates and proprietary technology to disclose the foreign jurisdictions where you have issued patents or pending patent applications, and the corresponding expiration dates (or expected expiration dates). |
Aerie acknowledges the Staff’s comment and will expand the Company’s disclosure regarding patent protection for current product candidates and proprietary technology to disclose the foreign jurisdictions where the Company has issued patents or pending patent applications, and the corresponding expiration dates (or expected expiration dates) in future filings.
* * *
Thank you for your attention to our response to your comment. Should any questions arise in connection with this response letter, please contact me at 908-947-3540.
Very truly yours,
AERIE PHARMACEUTICALS, INC. | ||
| By: | /s/ Richard J. Rubino | |
| Name: Richard J. Rubino | ||
| Title: Chief Financial Officer | ||
